Dermatology NewsPhase III Trial Activity for Melanoma Is Robust : Biologics being studied include CTLA4 blockers, apoptosis restorers, and antiangiogenesis agents.September 1, 2007Melanoma
Dermatology NewsU.K. Study Data Confirmed Safety of Diclofenac 3% for Actinic KeratosisSeptember 1, 2007Melanoma
Revisiting Tanning-Bed Legislation [editorial]August 1, 2007Nonmelanoma Skin CancerMelanomaAesthetic Dermatology
